Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 70, Issue 8, Pages 2379-2384Publisher
SPRINGER
DOI: 10.1007/s00262-021-02850-6
Keywords
Adult Burkitt's lymphoma; CAR-T cell therapy; Bulky disease; CAR-T cells expansion; Tumor microenvironment
Categories
Funding
- National Natural Science Foundation of China [81670150]
Ask authors/readers for more resources
The study evaluated the efficacy and safety of CAR19/22 T cell therapy in six refractory Burkitt's lymphoma cases, showing that three patients achieved an objective response and patients with bulky disease had poorer prognosis.
The treatment of refractory Burkitt's lymphoma (BL) is still a challenge. Although CAR-T cell therapy has achieved good responses in diffuse large B cell lymphoma, there is no case series report about the efficacy of CAR-T cell therapy in adult Burkitt's lymphoma. In this study, we evaluate the efficacy and safety of CAR19/22 T cell therapy in six refractory Burkitt's lymphoma cases with poor genetic prognostic factors. After CAR-T cell therapy, five cases had grade 1 and one had grade 3 cytokine release syndrome. Three patients achieved an objective response (3/6 50%), including two partial remission and one complete remission. One CR patient received allogeneic hematopoietic stem cell transplantation (HSCT) and one PR patient received CAR22/19-T cells following auto-HSCT, and they were still in remission at 37 and 22 months of follow-up, respectively. Interestingly, patients with bulky disease (case 2, 4 and 5) had higher levels of serum IL-2R, which was secreted by regulatory T cells, lower CAR lentiviral amplification and poorer prognosis with shorter survival time than cases with non-bulky disease. It is suggested that high tumor burden, more immune suppressive cells and limited CAR-T cell expansion might affect the efficacy of CAR-T cell therapy. CAR-T cell therapy in adult BL patients whose best response cannot achieve CR may need to bridge to other treatments (such as HSCT) early.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available